Inhibition of survivin with YM155 induces durable tumor response in anaplastic thyroid cancer

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4123-4132

  Mehta, Amit ^a,b   Zhang, Lisa ^a   Boufraqech, Myriem ^a   Liu Chittenden, Yi ^a   Zhang, Yaqin ^c   Patel, Dhaval ^a   Davis, Sean ^a   Rosenberg, Avi ^a   Ylaya, Kris ^a   Aufforth, Rachel ^a   Li, Zhuyin ^c   Shen, Min ^c   Kebebew, Electron ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEPANTRONIUM BROMIDE; SURVIVIN; BIRC5 PROTEIN, HUMAN; CLSPN PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; NAPHTHOQUINONE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA;

ANAPLASTIC THYROID CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; GENE EXPRESSION; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HELA CELL LINE; IC50; IMMUNOLOGY; METABOLISM; METASTASIS; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TREATMENT OUTCOME; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HELA CELLS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; INHIBITORY CONCENTRATION 50; MICE; NAPHTHOQUINONES; NEOPLASM METASTASIS; RNA, SMALL INTERFERING; S PHASE; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84942925453     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3251     Document Type: Article

References (34)

1. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: A review of epidemiology, pathogenesis, and treatment. J Oncol 2011;2011: 542358.
2. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103: 1330-5.
3. Granata R, Locati L, Licitra L. Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: Review of the current literature. Curr Opin Oncol 2013;25: 224-8.
4. NilubolN, Kebebew E. Should small papillary thyroid cancer be observed? A population-based study. Cancer 2015;121: 1017-24.
5. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009;8: 959-68.
6. Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, et al. Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol 2010;79: 1272-80.
7. Shum D, Smith JL, Hirsch AJ, Bhinder B, Radu C, Stein DA, et al. Highcontent assay to identify inhibitors of dengue virus infection. Assay Drug Dev Technol 2010;8: 553-70.
8. Shahinas D, Liang M, Datti A, Pillai DR. A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem 2010;53: 3552-7.
9. Zhang L, He M, Zhang Y, Nilubol N, Shen M, KebebewE.Quantitative highthroughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: Opportunities for repurposing. J Clin Endocrinol Metab 2012;97: E319-28.
10. Zhang L, Gaskins K, Yu Z, Xiong Y, Merino MJ, Kebebew E. An in vivo mouse model of metastatic human thyroid cancer. Thyroid 2014; 24: 695-704.
11. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008;26: 5198-203.
12. Segerhammar I, Larsson C, Nilsson IL, BackdahlM, Hoog A, Wallin G, et al. Anaplastic carcinoma of the thyroid gland: Treatment and outcome over 13 years at one institution. J Surg Oncol 2012;106: 981-6.
13. Onoda N, Kashiwagi S, Noda S, Kawajiri H, Takashima T, Ishikawa T, et al. High efficacy of chemoradiation therapy sensitized byweekly docetaxel for anaplastic thyroid cancer. Anticancer Res 2013;33: 3445-8.
14. Troch M, Koperek O, Scheuba C, Dieckmann K, Hoffmann M, Niederle B, et al. High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. J Clin Endocrinol Metab 2010;95: E54-7.
15. Wang Q, Chen Z, Diao X, Huang S. Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells. Cancer Lett 2011;302: 29-36.
16. Wang YF, Zhang W, He KF, Liu B, Zhang L, Zhang WF, et al. Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma. Apoptosis 2014;19: 748-58.
17. Petermann E, Helleday T, Caldecott KW. Claspin promotes normal replication fork rates in human cells. Mol Biol Cell 2008;19: 2373-8.
18. Smith-Roe SL, Patel SS, Zhou Y, Simpson DA, Rao S, Ibrahim JG, et al. Separation of intra-S checkpoint protein contributions to DNA replication fork protection and genomic stability in normal human fibroblasts. Cell Cycle 2013;12: 332-45.
19. Cheson BD, Bartlett NL, Vose JM, Lopez-Hernandez A, Seiz AL, Keating AT, et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012;118: 3128-34.
20. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009;27: 4481-6.
21. Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, et al. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2013;24: 2601-6.
22. Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009;15: 3872-80.
23. Tolcher AW, Quinn DI, Ferrari A, Ahmann F, Giaccone G, Drake T, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol 2012; 23: 968-73.
24. Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007;67: 8014-21.
25. Fara J, Mitchell C. The value of infusion and injection regimens in assessing efficacy and toxicity of drugs. Trends Pharmacol Sci 1986;5: 21-5.
26. Sikic BI, Collins JM, Mimnaugh EG, Gram TE. Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep 1978;62: 2011-7.
27. Hirokawa N. Microtubule organization and dynamics dependent on microtubule-associated proteins. Curr Opin Cell Biol 1994;6: 74-81.
28. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3: 917-21.
29. Ito Y, Yoshida H, Uruno T, Nakano K, Miya A, Kobayashi K, et al. Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma. Oncol Rep 2003;10: 1337-40.
30. Pannone G, Santoro A, Pasquali D, Zamparese R, Mattoni M, Russo G, et al. The role of survivin in thyroid tumors: Differences of expression in welldifferentiated, non-well-differentiated, and anaplastic thyroid cancers. Thyroid 2014;24: 511-9.
31. Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, et al. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas. Cancer Res 2007;67: 6574-81.
32. Allera-Moreau C, Rouquette I, Lepage B, Oumouhou N, Walschaerts M, Leconte E, et al. DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients. Oncogenesis 2012; 1: E30.
33. Benevolo M, Musio A, Vocaturo A, Dona MG, Rollo F, Terrenato I, et al. Claspin as a biomarker of human papillomavirus-related high grade lesions of uterine cervix. J Transl Med 2012;10: 132.
34. Cheng SM, Chang YC, Liu CY, Lee JY, Chan HH, Kuo CW, et al. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Br J Pharmacol 2015;172: 214-34.